Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 130

1.
2.

Enhanced therapeutic efficacy of G207 for the treatment of glioma through Musashi1 promoter retargeting of gamma34.5-mediated virulence.

Kanai R, Tomita H, Shinoda A, Takahashi M, Goldman S, Okano H, Kawase T, Yazaki T.

Gene Ther. 2006 Jan;13(2):106-16.

PMID:
16163378
3.
5.

Development of a second-generation oncolytic Herpes simplex virus expressing TNFalpha for cancer therapy.

Han ZQ, Assenberg M, Liu BL, Wang YB, Simpson G, Thomas S, Coffin RS.

J Gene Med. 2007 Feb;9(2):99-106.

PMID:
17256802
6.

ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties.

Liu BL, Robinson M, Han ZQ, Branston RH, English C, Reay P, McGrath Y, Thomas SK, Thornton M, Bullock P, Love CA, Coffin RS.

Gene Ther. 2003 Feb;10(4):292-303.

PMID:
12595888
7.

Neurovirulent factor ICP34.5 uniquely expressed in the herpes simplex virus type 1 Delta gamma 1 34.5 mutant 1716.

Holman HA, MacLean AR.

J Neurovirol. 2008 Jan;14(1):28-40. doi: 10.1080/13550280701769999.

PMID:
18300073
8.
9.

Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing.

Todo T, Martuza RL, Rabkin SD, Johnson PA.

Proc Natl Acad Sci U S A. 2001 May 22;98(11):6396-401.

10.

Assessment in vitro of a novel therapeutic strategy for glioma, combining herpes simplex virus HSV1716-mediated oncolysis with gene transfer and targeted radiotherapy.

Quigg M, Mairs RJ, Brown SM, Harland J, Dunn P, Rampling R, Livingstone A, Wilson L, Boyd M.

Med Chem. 2005 Sep;1(5):423-9.

PMID:
16787326
11.

Positron emission tomography-based imaging of transgene expression mediated by replication-conditional, oncolytic herpes simplex virus type 1 mutant vectors in vivo.

Jacobs A, Tjuvajev JG, Dubrovin M, Akhurst T, Balatoni J, Beattie B, Joshi R, Finn R, Larson SM, Herrlinger U, Pechan PA, Chiocca EA, Breakefield XO, Blasberg RG.

Cancer Res. 2001 Apr 1;61(7):2983-95.

12.

Treatment of malignant gliomas with a replicating adenoviral vector expressing herpes simplex virus-thymidine kinase.

Nanda D, Vogels R, Havenga M, Avezaat CJ, Bout A, Smitt PS.

Cancer Res. 2001 Dec 15;61(24):8743-50.

13.
14.

Antitumor efficacy of 34.5ENVE: a transcriptionally retargeted and "Vstat120"-expressing oncolytic virus.

Yoo JY, Haseley A, Bratasz A, Chiocca EA, Zhang J, Powell K, Kaur B.

Mol Ther. 2012 Feb;20(2):287-97. doi: 10.1038/mt.2011.208.

15.

DNA demethylating agents synergize with oncolytic HSV1 against malignant gliomas.

Okemoto K, Kasai K, Wagner B, Haseley A, Meisen H, Bolyard C, Mo X, Wehr A, Lehman A, Fernandez S, Kaur B, Chiocca EA.

Clin Cancer Res. 2013 Nov 1;19(21):5952-9. doi: 10.1158/1078-0432.CCR-12-3588.

17.

Oncolytic virus therapy using genetically engineered herpes simplex viruses.

Todo T.

Front Biosci. 2008 Jan 1;13:2060-4. Review.

PMID:
17981691
18.

Enhanced cytotoxicity with a novel system combining the paclitaxel-2'-ethylcarbonate prodrug and an HSV amplicon with an attenuated replication-competent virus, HF10 as a helper virus.

Ishida D, Nawa A, Tanino T, Goshima F, Luo CH, Iwaki M, Kajiyama H, Shibata K, Yamamoto E, Ino K, Tsurumi T, Nishiyama Y, Kikkawa F.

Cancer Lett. 2010 Feb 1;288(1):17-27. doi: 10.1016/j.canlet.2009.06.014.

PMID:
19604626
19.
20.

Evaluation of genetically engineered herpes simplex viruses as oncolytic agents for human malignant brain tumors.

Andreansky S, Soroceanu L, Flotte ER, Chou J, Markert JM, Gillespie GY, Roizman B, Whitley RJ.

Cancer Res. 1997 Apr 15;57(8):1502-9.

Supplemental Content

Support Center